Earnings Call for Q4FY21 of Aarti Drugs
Conference Call with Aarti Drugs Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.17-05-2021
17-05-2021
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith Results Presentation for the Quarter and year ended March 31, 2021 for your records.17-05-2021
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find attached herewith press release on the Financial Results for the quarter and year ended March 31, 2021.16-05-2021
AARTI DRUGS LTD. - 524348 - Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2021
We wish to inform you that Board of Directors at its Meeting held on Saturday, May 15, 2021, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Year ended March 31, 202115-05-2021
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Conference Call for the Investors and Analysts has been scheduled on Monday, May 17, 2021 at 4:00 PM IST to discuss the Company's financial performance for the Quarter and year ended March 31, 2021.13-05-2021
Aarti Drugs Ltd - 524348 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended March 31, 2021
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2021 ,inter alia, to consider and approve This is to inform you that next Board Meeting of the Board of Directors of the Company is scheduled to be held on Saturday, May 15, 2021 to consider, approve and take on record Audited Financial Results for the Quarter and year ended March 31, 2021.08-05-2021
Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, We wish to inform you that CRISIL Limited has reaffirmed credit rating on the bank facilities of the company.03-05-2021
Aarti Drugs Set To Open Share Buyback Offer On April 27
Aarti Drugs: The buyback offer will comprise 6 lakh fully paid-up equity shares with a face value of Rs 10 each, representing 0.64 per cent of total shares of the company21-04-2021
Aarti Drugs Ltd - 524348 - Letter of Offer
Inga Ventures Pvt Ltd ("Manager to the Buyback Offer") has submitted to BSE a copy of Letter of Offer to the Equity Shareholders/ Beneficial owners of Equity Shares of Aarti Drugs Ltd ("Target Company").20-04-2021